ClinicalTrials.gg
Status unknownNCT05110807Updated Feb 14, 2022

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

A Phase 1 interventional study of TQB3617 in Advanced Malignant Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

TQB3617 is a bromodomain and extra-terminal (BET) inhibitor that can competitively bind to bromodomains (BRDs) with Acetylated lysine(Kac) and block or partially block the role of KAc in subsequent gene transcription and regulation of chromatin structure, thereby playing an anti-tumor role.

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged: ≥18 years old.
  • (ECOG) performance status of 0 to 2.
  • ≥ 3 months.
  • Patients with advanced tumor who have failed standard treatment or are unable to receive standard treatment or have no effective treatment.
  • Female and male subjects should agree to use an adequate method of starting with signing form (ICF) through 180 days after the last dose of study. The women of reproductive age who blood/urine results were positivetherapy before the first study drug is administered within less than 7 days.

Exclusion criteria

Exclusion Criteria:

  • Patients has had or is currently having other malignant tumors within 3 years.
  • Patients have multiple factors that affect their oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction).
  • The patient had unmitigated toxic reactions due to any prior treatment.
  • Patients underwent major surgical treatment, open , or significant traumatic injury within 4 weeks prior to the start of study treatment.
  • Patients have long - term unhealed wounds or fractures.
  • Patients were taking Cytochrome P450 3A4, Cytochrome P450 3A5, Cytochrome P450 2A6, Cytochrome P450 2D6 (, CYP3A5, CYP2A6,CYP2D6) inhibitors or inducers before oral medication.
  • Patients who, in the investigator's judgment, have a comorbidity that seriously endangers patient safety or interferes with study completion, or who are considered unsuitable for inclusion for other reasons.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    TQB3617

    0.1mg, once daily, was used as the initial dose, and the medication stage was divided into single administration and continuous administration stages. The single administration was given once, and the continuous administration stage was entered 7 days after drug withdrawal. The drug was administered continuously until the disease progressed.

    Drug: TQB3617

Interventions

  • DrugTQB3617

    TQB3617 is a BET inhibitor.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    The highest dose of a drug or treatment that does not cause unacceptable side effects.

    Time frame: Baseline up to 48 weeks

  2. Adverse events (AEs) and serious adverse events (SAEs)

    The occurrence of all AEs and SAEs

    Time frame: Baseline up to 48 weeks

Secondary outcomes

  1. Time to reach maximum (peak) plasma concentration following drug administration(Tmax)

    To characterize the pharmacokinetics of TQB3617 by assessment of time to reach maximum plasma concentration after single and multiple dosing

    Time frame: Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8,12, 24, 48, 72, 96, 120,168 hours after oral administration of a single drug delivery; 30 minutes, 1, 2, 3, 4, 6, 8,12, 24 hours of day 28; 30 minutes before oral administration on day 8, day 15, day 22, day 28.

  2. Maximum (peak) plasma drug concentration (Cmax)

    Cmax is the maximum plasma concentration of TQB3617 or metabolite(s).

    Time frame: Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8,12, 24, 48, 72, 96, 120,168 hours after oral administration of a single drug delivery; 30 minutes, 1, 2, 3, 4, 6, 8,12, 24 hours of day 28; 30 minutes before oral administration on day 8, day 15, day 22, day 28.

  3. Elimination half-life (to be used in one-or non- compartmental model) (t1/2)

    t1/2 is time it takes for the blood concentration of TQB3617 or metabolite(s) to drop by half.

    Time frame: Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8,12, 24, 48, 72, 96, 120,168 hours, after oral administration of a single drug delivery.

  4. Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)

    Maximum (peak) steady-state plasma drug concentration during a dosage interval

    Time frame: Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8,12, 24, 48, 72, 96, 120,168 hours after oral administration of a single drug delivery; 30 minutes, 1, 2, 3, 4, 6, 8,12, 24 hours of day 28; 30 minutes before oral administration on day 8, day 15, day 22, day 28.

  5. Minimum steady-state plasma drug concentration during a dosage interval (Css-min)

    Minimum steady-state plasma drug concentration during a dosage interval

    Time frame: Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8,12, 24, 48, 72, 96, 120,168 hours after oral administration of a single drug delivery; 30 minutes, 1, 2, 3, 4, 6, 8,12, 24 hours of day 28; 30 minutes before oral administration on day 8, day 15, day 22, day 28.

  6. Concentration at the end of the dosing interval AUCtau,ss

    To characterize the pharmacokinetics of TQB3617 by assessment of area the concentration at the end of the administration interval

    Time frame: Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8,12, 24, 48, 72, 96, 120,168 hours after oral administration of a single drug delivery; 30 minutes, 1, 2, 3, 4, 6, 8,12, 24 hours of day 28; 30 minutes before oral administration on day 8, day 15, day 22, day 28.

  7. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 96 weeks

  8. Progress Free Survival(PFS)

    From the start of randomization to the first tumor progression or time of death.

    Time frame: up to 96 weeks

  9. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  10. Duration of Response (DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 96 weeks

  11. Overall Survival(OS)

    From date of first administration of test drug until the date of death from any cause,

    Time frame: assessed up to 100 months

07

Study locations

2 of 2 sites recruiting
  • Sun Yat-sen University Cancer Cen
    Guangzhou, Guangdong 510060, China
    Recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 31002, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Oct 2022, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2021
First posted
Nov 8, 2021
StartActual
Jan 5, 2022
Primary completionEst.
Oct 2022
CompletionEst.
Dec 2022
Last update
Feb 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05110807
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Jan 5, 2022
Primary completion
Oct 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Feb 14, 2022

Study contacts

Xiaojia Wang, Master
Contact
huang_jian22@aliyun.com
0571-88122146

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion